Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients
Preemptive pharmacogenomic testing for TPMT and NUDT15 polymorphisms before initiation of maintenance therapy for pediatric ALL patients yielded considerable cost savings.
Authors
- Jenny Q. Nguyen (ORCID: https://orcid.org/0009-0001-7190-1231)
- Simran D. S. Maggo (ORCID: https://orcid.org/0000-0002-7779-5206)
- Teresa Rushing (ORCID: https://orcid.org/0000-0002-3655-7957)
- Deepa Bhojwani (ORCID: https://orcid.org/0000-0002-7559-7927)
- Melanie Burgos
- Beverly Fuerte
- Cynthia L. Gong (ORCID: https://orcid.org/0000-0003-0159-1335)
- Van Thang Cao
Institutions
- University of Southern California (US)
- Children's Hospital of Los Angeles (US)
- Shenandoah University (US)
Publication Details
- Journal
- Pharmacogenetics and Genomics
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1097/fpc.0000000000000550
- Citations
- 1
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.54